# OnCo record nct07100080 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07100080/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07100080", "NCT07100080" ;
  schema:name "Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy"@en ;
  schema:alternateName "IZABRIGHT-Lung01"@en ;
  schema:description "A phase 2/3 trial of Izalontamab brengitecan, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07100080/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07100080> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2025-11-05" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/bms/> .